Live Breaking News & Updates on Yingyao Shao

Stay updated with breaking news from Yingyao shao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antisense oligonucleotides as a feasible therapy to treat MECP2 duplication disorder


 E-Mail
Many cognitive neurodevelopmental disorders are a result of too many or too few copies of certain genes or chromosomes. To date, no treatment options exist for this class of disorders. MECP2 duplication syndrome (MDS) is one such disorder that primarily affects boys and results from a duplication spanning the methyl-CpG binding protein 2 (MECP2) locus located on the X chromosome.
A preclinical study published from the laboratory of Dr. Huda Zoghbi, professor at Baylor College of Medicine and director of the Jan and Dan Duncan Neurological Research Institute at Texas Children s Hospital, provides experimental evidence that supports the use of antisense oligonucleotides as a feasible strategy to treat MDS. The study also offers crucial insights into the pharmacodynamics of this approach, which will serve as an important guide for the design and implementation of future clinical trials for this disorder. The study appears in the journal ....

United States , Baylor College Of Medicine , Alexanderj Trostle , Sameers Bajikar , Qi Wang , Frank Rigo , Huda Zoghbi , Yehezkel Sztainberg , Paymaan Jafar Nejad , Zhandong Liu , Jianrong Tang , Yingyao Shao , Regeneron Pharmaceuticals , Chao Family Foundation , Hamill Foundation , National Institutes Of Health , Huffington Foundation , Rett Syndrome Research , Ionis Pharmaceuticals , Cockrell Family Foundation , Research Institute Of Texas , Howard Hughes Medical Institute , Baylor College , Dan Duncan Neurological Research Institute , Texas Children , Science Translational ,